School of Information Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, China.
School of Medical Imaging, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Mol Cancer. 2023 Aug 30;22(1):143. doi: 10.1186/s12943-023-01808-9.
Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy.
The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules.
BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic.
传统的放疗和化疗在肿瘤治疗中的作用已得到深入研究。然而，这些治疗方法常常会给患者带来副作用，因此需要开发新的肿瘤治疗选择。B 细胞淋巴瘤-2（Bcl-2）/腺病毒 E1B 19kDa 相互作用蛋白 3（BNIP3）在肿瘤细胞中具有诱导凋亡的作用，与多种肿瘤的发生和治疗有关。然而，其在肿瘤诊断和靶向治疗中的潜在作用知之甚少。
研究结果表明，BNIP3 与组蛋白去乙酰化酶 1（HDAC1）的相互作用可能影响乳腺癌浸润性（BRCA）、肉瘤（SARC）、肾透明细胞癌（KIRC）和低级别胶质瘤（LGG）的进展。BNIP3 似乎主要通过基因沉默和整合体复合物在 BRCA 和 SARC 中发挥作用，而在 KIRC 和 LGG 中主要通过影响嗅觉功能发挥作用，这表明可以基于上述信号通路和下游分子开发靶向治疗。
BNIP3 已成为 BRCA、SARC、KIRC 和 LGG 的有前途的治疗和诊断靶点，为临床肿瘤分子治疗提供了新的见解。
Zotero 插件